## 略号一覧

ADA	adenosine deaminase	FVC	forced vital capacity
AIDS	acquired immunodeficiency syn-	HIV	human immunodeficiency virus
	drome	НОТ	home oxygen therapy
ALA	American Lung Association	IGRA	interferon-gamma release assay
AM	atypical mycobacteriosis	IL	interleukin
ARDS	acute respiratory distress syndrome	INH	isonicotinic acid hydrazide / isoni-
ARI	annual risk of infection		azid
ARTI	annual risk of infection	IPPB	intermittent positive pressure breath-
BAE	bronchial artery embolizaion		ing
BAG	bronchial arteriography	IRS	immune reconstitution syndrome
BAL	bronchoalveolar lavage	ISTC	International Standards of Tubercu-
BCG	Bacille de Calmette-Guérin		losis Care
BE	breathing exercise	IUATLD	International Union Against Tuber-
BG	bronchography		culosis and Lung Diseases
BGA	blood gas analysis	JATA	Japan Anti-Tuberculosis Associa-
CMI	cell-mediated immunity		tion
COPD	chronic obstructive pulmonary dis-	JICA	Japan International Cooperation
	ease		Agency
<b>CPFX</b>	ciprofloxacin	KM	kanamycin
CPM	capreomycin	LPT	lung physical therapy
CR	computed radiography	MAC	Mycobacterium avium complex
CS	cycloserine	MDP	muramyl dipeptide
CT	computed tomography	MDR	multi-drug resistance
DHSM	dihydrostreptomycin	MDRTB	multi-drug resistant tuberculosis
DNCB	Dinitrochlorobenzene	MGIT	Mycobacterium growth indicator
DOTS	Directly Observed Treatment,		tube
	Short-course	MHC	major histocompatibility complex
DTH	delayed-type hypersensitivity	MIC	minimal inhibitory concentration
EB	ethambutol	MMR	mass miniature radiophotography
<b>ELISA</b>	enzyme-linked immunosorbent assay	MRI	magnetic resonance imaging
ESR	erythrocyte sedimentation rate	NAP	p-nitro- $α$ -acetylamino- $β$ -hydroxy-
EVM	enviomycin		propiophenone
FDA	Fluorescein diacetate	NPPV	noninvasive positive pressure ven-
$\mathbf{FEV}_1$	forced exspiratory volume in one		tilation
	second	NTA	National Tuberculosis Association
FEV <sub>1</sub> %	one second forced expiratory vol-	NTM	nontuberculous mycobacteriosis
	ume rate	OFLX	ofloxacin

OT	occupational therapycoccupational	RFP	rifampicin
	therapist	RHF	right-sided heart failure
PaCO <sub>2</sub>	arterial carbon dioxide partial pres-	RP	radiophotography
	sure	RR	relative risk
$PaO_2$	arterial oxygen partial pressure	SaO <sub>2</sub>	arterial oxygen saturation
PAS	para-amino-salicylic acid	SCC	short course chemotherapy
PCR	polymerase chain reaction	SM	streptomycin
PD	postural drainage	Tb₁	thioacetazone
PEEP	positive end-expiratory pressure	TBGL	Tuberculous Glycolipids
	ventilation	TBLB	transbronchial lung biopsy
pН	hydrogen exponent	Tc	cytotoxic T cells
PPD	purified protein derivative	TH	ethionamide
PPM	private public mix	Th	helper T cells
PPP	public private partnership	VATS	video-assisted thoracoscopic sur-
PPT	pulmonary physical therapy		gery
PT	physical therapy / physical thera-	VC	vital capacity
	pist	VM	viomycin
PZA	pyrazinamide	$VO_2$	oxygen uptake
QFT	QuantiFERON-TB	WHO	World Health Organization
RFLP	restriction fragment length polymorphism	XDR	extensively drug-resistant